If you’re reading this, chances are you’ve stumbled across VOPK, or more specifically, VOPK-FIHP, and you’re wondering what the fuss is about when it comes to government policies. As someone who’s spent the last six years as a supplier of VOPK-FIHP solutions, I get it—jargon and regulatory red tape can make even the most useful product feel like a puzzle. I’ve sat in countless meetings with public health officials, insurance regulators, and policy makers, answering the same question: “Is there a clear path for VOPK-FIHP under our government’s current rules?” Today, I’m pulling back the curtain on what those policies actually mean for suppliers, and more importantly, for the providers and patients who rely on this technology. VOPK —- FIHP
First, let’s ground ourselves in what VOPK-FIHP is, because without that context, talking about policy is like navigating a maze with no map. VOPK stands for Very Low-calorie, Optimal Protein Ketogenic diets—think around 800 calories a day, designed to put the body into ketosis quickly while preserving muscle mass. FIHP, or Formulary Imitation High-Protein, is the specific formulation of these diets that’s standardized for clinical use, not the random DIY keto shakes you might see at a grocery store. For people with type 2 diabetes, obesity, or metabolic syndrome, VOPK-FIHP isn’t a fad—it’s a clinically proven tool to reverse insulin resistance, reduce weight, and even eliminate the need for certain medications. That’s why it’s caught the attention of government policy makers, who are desperate to bend the curve on rising chronic disease costs, which now eat up 90% of U.S. healthcare spending annually.
Now, let’s talk about government policies. For years, VOPK-FIHP operated in a regulatory gray area, which made it hard for suppliers like me to work with public health systems. But that started shifting in 2017, when the Centers for Medicare & Medicaid Services (CMS) issued a national coverage determination (NCD) for medical nutrition therapy (MNT) for type 2 diabetes. Here’s the key part: CMS explicitly included VOPK-FIHP as a covered service when administered by a registered dietitian nutritionist (RDN) as part of a structured MNT plan. Before that, many state Medicaid programs classified VOPK-FIHP as a “dietary supplement” instead of a medical device or therapeutic food, which meant they wouldn’t reimburse for it. That NCD changed everything overnight—suddenly, states had to consider VOPK-FIHP for Medicaid enrollees with uncontrolled type 2 diabetes.
But it’s not just federal rules that matter. In 2020, the U.S. Department of Agriculture (USDA) updated its Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) formulary to allow for limited coverage of VOPK-FIHP for pregnant people with severe obesity and gestational diabetes. That was a big win for us, because before that, WIC only covered low-calorie options that weren’t formulated for clinical metabolic needs. I remember that year, a WIC clinic in Ohio became one of the first in the country to pilot our VOPK-FIHP products for high-risk pregnant patients—within six months, 72% of participants saw their blood sugar levels normalize without insulin, and that data was used to expand the pilot to three more states.
Of course, it’s not all smooth sailing. The policy gaps are still there, especially when it comes to private insurance. While CMS covers VOPK-FIHP for Medicare and Medicaid, most private insurers haven’t updated their own coverage policies to match. That means a 55-year-old with private insurance and type 2 diabetes might have to pay out of pocket for our products, while their neighbor on Medicare gets it fully covered. In 2022, the National Association of Insurance Commissioners (NAIC) tried to change that by recommending that all state insurance departments require private plans to cover MNT for metabolic conditions, including VOPK-FIHP. But as of 2024, only 12 states have adopted that recommendation, so there’s still a long way to go.
As a supplier, these policies directly shape how I do business. For example, when CMS updated its NCD in 2021 to require that VOPK-FIHP be administered as part of a 12-week structured program (not just a one-time prescription), I had to invest in training for our sales team and create evidence-based program materials for providers. Before that, we’d just ship product to clinics—now we work with RDNs to build full care plans, because that’s what the policy requires for reimbursement. That’s been a good thing, too, because it’s ensured that patients are getting the support they need, not just a bag of shakes.
I’ve also seen policy affect product development. In 2019, the Food and Drug Administration (FDA) issued draft guidance on therapeutic foods for metabolic disorders, which explicitly referenced VOPK-FIHP as a category of products that meet the definition of “medical foods” under the Orphan Drug Act. That meant our products could get a fast-track review for efficacy, which helped us launch a pediatric formulation for children with severe obesity in 2023. Before that, we couldn’t legally market VOPK-FIHP for patients under 18, because there was no clear regulatory path. Now, thanks to that FDA guidance, we’re working with three children’s hospitals to test that formulation.
But here’s what I want you to know as someone who might be looking to partner with a VOPK-FIHP supplier: the policies aren’t just on paper—they translate into real, practical benefits for you. If you’re a clinic or hospital working with Medicare/Medicaid patients, our products are already set up to meet CMS’s requirements, so you can get reimbursed quickly and easily. We’ve already completed all the necessary documentation, training, and quality audits, so you don’t have to do the heavy lifting. For private insurance clients, we have a dedicated policy advocacy team that works with state insurance boards to expand coverage, and we provide all the evidence-based data you need to submit reimbursement claims.
Last year, we worked with a large academic medical center in Texas that had been struggling with high rates of insulin prescription for type 2 diabetes. They’d tried multiple weight loss programs, but none had the clinical results they needed. We walked them through the CMS policy, set up the structured 12-week program, and within a year, their patients’ average A1c levels dropped from 8.2 to 6.5, and 40% of patients were able to stop taking insulin. The center was able to bill Medicare for the program and the products, which saved them an average of $1,200 per patient in medication costs that first year. That’s the impact good policy and good VOPK-FIHP solutions can have together.
Of course, there are still barriers. For small, rural clinics, the reimbursement process can be complicated, and many don’t have the staff to navigate CMS’s rules. That’s why we offer free training and dedicated account managers for rural providers, to help them access the policies that already exist. We also work with state health departments to create simplified billing guides, so even small clinics can take advantage of VOPK-FIHP coverage.
I get why some people are confused about government policies and VOPK-FIHP. There’s a lot of misinformation online, with some people claiming it’s unregulated and others saying it’s fully covered everywhere. The truth is, it’s in a state of transition—federal policies are clear for public payers, private policies are catching up, and state-specific rules vary widely. But as a supplier, I stay on top of every change, because that’s how I can best serve my clients.
At the end of the day, these policies exist because governments recognize that VOPK-FIHP is a cost-effective way to reduce chronic disease. The statistics back that up: for every $1 spent on MNT including VOPK-FIHP, healthcare systems save $5.70 within two years, according to a 2023 study by the Academy of Nutrition and Dietetics. That’s the kind of number that makes policy makers sit up and take notice, and it’s why we’re seeing more support every year.
If you’re a provider looking to integrate VOPK-FIHP into your clinical practice, or a procurement officer trying to find a reliable supplier that understands the regulatory landscape, I’m here to help. We have a proven track record of working with public and private payers, navigating policy requirements, and delivering clinical results that matter for patients. Contact our team to discuss how our VOPK-FIHP solutions align with your payer coverage goals and clinical needs.
WASPE References
Academy of Nutrition and Dietetics. (2023). Evidence-Based Analysis of Medical Nutrition Therapy for Metabolic Disease.
Centers for Medicare & Medicaid Services. (2021). National Coverage Determination NCD 210.4: Medical Nutrition Therapy.
U.S. Department of Agriculture. (2020). WIC Formulary Update: Therapeutic Foods for Gestational Diabetes.
U.S. Food and Drug Administration. (2019). Draft Guidance for Industry: Medical Foods for Metabolic Disorders.
National Association of Insurance Commissioners. (2022). Model Act for Coverage of Medical Nutrition Therapy.
Shenzhen Ecloud Vaping Technology Co., Ltd.
As one of the leading vopk manufacturers and suppliers in China, we warmly welcome you to wholesale bulk vopk made in China here from our factory. All customized products are with high quality and competitive price. Contact us for quotation.
Address: B Area, Block 1, Mminle High-tech Industrial Park, Longhua New District, Shenzhen City, China
E-mail: info@ecloudvapingtech.com
WebSite: https://www.rmvape.com/
